greenlifescience

Clinical Research Hiring Trends 2026: Site-Level Demand, PI Scarcity & Market Growth By Daniel Bishop, Clinical Research Recruitment Specialist April 16th 2026 Clinical Research Hiring Trends Heading into 2026 Our internal placement data highlights a clear structural trend within the clinical research market. Demand remains heavily weighted toward clinical and site-level functions, with hiring volumes […]

CRO Hiring Trends 2026: BD Attrition, Salaries & Market Demand By Robert Green, CRO Commercial Headhunter April 16th 2026 CRO Hiring Trends Heading into 2026 Our internal data from 2025 highlights a clear shift in the CRO market – particularly within business development hiring and attrition trends. Most notably, we saw 21% movement in 2025,

What Private Equity Firms Look for When Scaling CRO Commercial Teams By Robert Green, CRO Commercial Headhunter April 16th 2026 When private equity firms assess a CRO, they’re not just evaluating revenue growth. They’re assessing how that revenue is built. At first glance, a CRO showing strong growth can look attractive. But experienced investors quickly

What Separates a £5M BD Manager from a £50M CRO Revenue Leader By Robert Green, CRO Commercial Headhunter April 15th 2026 One of the most important inflexion points in any scaling CRO is the shift from tactical selling to becoming a CRO revenue leader. On the surface, the roles can look similar. But the difference

CRO Revenue Stalling? It’s Usually Not a Sales Problem By Robert Green, CRO Commercial Headhunter April 15th 2026 Over the past 12–18 months, I’ve had repeated conversations with CRO CEOs hearing the same thing: “We have strong BD people.”“They’re active.”“They’re busy.”“But growth has plateaued.” When CRO revenue stalls, the default assumption is that it’s a

Why Most CRO Business Development Hires Fail Within 18 Months (And How to Avoid It) By Robert Green, CRO Commercial Headhunter April 15th 2026 After analysing CRO commercial hiring trends across the US and Europe in 2025, one pattern stands out clearly: Business Development is the least stable function inside a Contract Research Organisation (CRO).

10th April 2026 Developments across the global biotechnology and pharmaceutical sector this week highlight an increasingly complex and interconnected environment, shaped by scientific progress, strategic transactions, regulatory oversight, and geopolitical dynamics. Activity spanned acquisitions, licensing agreements, capital markets events, clinical and safety updates, as well as manufacturing investment and supply chain disruption. Taken together, these